Deutsch English Français

Contact

EP3359188

European procedure

Quick help

Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...

News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...

Extract from the Register of European Patents

EP About this file: EP3359188

EP3359188 - STREPTOCOCCUS SUIS POLYSACCHARIDE-PROTEIN CONJUGATE COMPOSITION [Right-click to bookmark this link]
Status	The application is deemed to be withdrawn Status updated on 03.09.2021 Database last updated on 02.09.2024
Former	Examination is in progress Status updated on 30.10.2020
Former	Request for examination was made Status updated on 13.07.2018
Former	The international publication has been made Status updated on 18.04.2017
Former	unknown Status updated on 03.01.2017
Most recent event Tooltip	03.09.2021	Application deemed to be withdrawn	published on 06.10.2021 [2021/40]
Applicant(s)	For all designated states Boehringer Ingelheim Animal Health USA Inc. 3239 Satellite Blvd Duluth, GA 30096 / US
	For all designated states UNIVERSITE DE MONTREAL 2900, Boulevard Edouard-Monpetit Montreal, Quebec H3T 1J4 / CA
	For all designated states Université Du Québec À Montréal 130 Saint-Denis Street P.O. Box 8888 Station Centre-Ville Montréal, Québec H3C 3P8 / CA
	[2019/19]
Former [2018/33]	For all designated states Boehringer Ingelheim Vetmedica, Inc. 2621 North Belt Highway St. Joseph, MO 64506 / US
	For all designated states UNIVERSITE DE MONTREAL 2900, Boulevard Edouard-Monpetit Montreal, Quebec H3T 1J4 / CA
	For all designated states Université Du Québec À Montréal 130 Saint-Denis Street P.O. Box 8888 Station Centre-Ville Montréal, Québec H3C 3P8 / CA
Inventor(s)	01 / GOTTSCHALK, Marcelo Université de Montréal 3200 Rue Sicotte Saint-Hyacinthe, Québec J2S 2M2 / CA
	02 / GOYETTE-DESJARDINS, Guillaume Université de Montréal 3200 Rue Sicotte Saint-Hyacinthe, Québec J2S 2M2 / CA
	03 / KEMPKER, Jennifer Anne 802 SW Savannah Drive Lee's Summit, Missouri 64081 / US
	04 / NEUBAUER, Axel c/o VP IP Legal Boehringer Ingelheim USA Corp., 900 Ridgebury Rd., P.O. Box 368 Ridgefield, Connecticut 06877-0368 / US
	05 / ROY, René Université du Québec à Montréal 1430 Saint-Denis P.O. Box 8888 Station Centre-Ville Montréal, Québec H3C 3P8 / CA
	06 / SEGURA, Mariela Université de Montréal 3200 Rue Sicotte Saint-Hyacinthe, Québec J2S 2M2 / CA
	07 / SHIAO, Tze Chieh Université du Québec à Montréal 1430 Saint-Denis P.O. Box 8888 Station Centre-Ville Montréal, Québec H3C 3P8 / CA
	[2018/33]
Representative(s)	Simon, Elke Anna Maria, et al Boehringer Ingelheim GmbH Binger Strasse 173 55216 Ingelheim am Rhein / DE
	[2018/33]
Application number, filing date	16782376.4	06.10.2016
	[2018/33]
	WO2016US55658
Priority number, date	US201562238516P	07.10.2015 Original published format: US 201562238516 P
	[2018/33]
Filing language	EN
Procedural language	EN
Publication	Type:	A1 Application with search report
	No.:	WO2017062558
	Date:	13.04.2017
	Language:	EN
	[2017/15]
	Type:	A1 Application with search report
	No.:	EP3359188
	Date:	15.08.2018
	Language:	EN
	The application published by WIPO in one of the EPO official languages on 13.04.2017 takes the place of the publication of the European patent application.
	[2018/33]
Search report(s)	International search report - published on:	EP	13.04.2017
Classification	IPC:	A61K39/09	[2018/33]
	CPC:	A61K39/092 (EP,US); A61K2039/55544 (EP,US); A61K2039/55566 (EP,US); A61K2039/575 (EP,US); A61K2039/70 (US)
Designated contracting states	AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2018/33]
Title	German:	STREPTOCOCCUS-SUIS-POLYSACCHARID-PROTEIN-KONJUGATZUSAMMENSETZUNG	[2018/33]
	English:	STREPTOCOCCUS SUIS POLYSACCHARIDE-PROTEIN CONJUGATE COMPOSITION	[2018/33]
	French:	COMPOSITION DE CONJUGUÉS POLYSACCHARIDE STREPTOCOCCUS SUIS-PROTÉINE	[2018/33]
Entry into regional phase	07.05.2018	National basic fee paid
	07.05.2018	Designation fee(s) paid
	07.05.2018	Examination fee paid
Examination procedure	04.05.2018	Date on which the examining division has become responsible
	07.05.2018	Examination requested [2018/33]
	07.12.2018	Amendment by applicant (claims and/or description)
	29.10.2020	Despatch of a communication from the examining division (Time limit: M06)
	11.05.2021	Application deemed to be withdrawn, date of legal effect [2021/40]
	02.06.2021	Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time [2021/40]
Fees paid	Renewal fee
	31.10.2018	Renewal fee patent year 03
	31.10.2019	Renewal fee patent year 04
	02.11.2020	Renewal fee patent year 05
Opt-out from the exclusive Tooltip competence of the Unified Patent Court	See the Register of the Unified Patent Court for opt-out data
	Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited in	International search	[Y]WO2012035519 (NOVARTIS AG [CH], et al) [Y] 1-20 * the whole document * * in particular, the claims and the examples *;
		[IP]WO2016134485 (VAXALTA INC [CA]) [IP] 1-20 * paragraph [0011] * * paragraph [0168] * * paragraph [0170] *;
		[Y] - CALZAS CYNTHIA ET AL, "Group B Streptococcus and Streptococcus suis Capsular Polysaccharides Induce Chemokine Production by Dendritic Cells via Toll-Like Receptor 2-and MyD88-Dependent and -Independent Pathways", INFECTION AND IMMUNITY, (201309), vol. 81, no. 9, pages 3106 - 3118, XP002765279 [Y] 1-20 * abstract * * page 3112, column r, paragraphs 1, 2 *
		[XP] - GOYETTE-DESJARDINS GUILLAUME ET AL, "Protection against Streptococcus suis Serotype 2 Infection Using a Capsular Polysaccharide Glycoconjugate Vaccine", INFECTION AND IMMUNITY, (201607), vol. 84, no. 7, ISSN 0019-9567, pages 2059 - 2075, XP002765280 [XP] 1-20 * the whole document *
	by applicant	US2909462
		US7709001
		- GOTTSCHALK, Diseases of swine, (2012), pages 841 - 55
		- FIELD ET AL., VET REC., (1954), vol. 66, pages 453 - 5
		- JANSEN; DORSSEN, TIJDSCHR DIERGENEESKD., (1951), vol. 76, pages 815 - 32
		- DE MOOR CE., ANTONIE VAN LEEUWENHOEK, (1963), vol. 29, pages 272 - 80
		- ELLIOTT SD., J HYG (LOND)., (1966), vol. 64, pages 205 - 12
		- WINDSOR; ELLIOTT, J HYG (LOND, (1975), vol. 75, pages 69 - 78
		- GOYETTE-DESJARDINS ET AL., EMERG MICROBES. INFECT, (2014), vol. 3, page E45
		- HIGGINS; GOTTSCHALK, DISEASES OF SWINE, (2006), pages 769 - 83
		- SANFORD; TILKER, J AM VET MED ASSOC., (1982), vol. 181, pages 673 - 6
		- CLOUTIER, VET MICROBIOL., (2003), vol. 97, pages 135 - 51
		- SEGURA M., CAN J MICROBIOL, (2012), vol. 58, pages 249 - 60
		- GOTTSCHALK, DISEASES OF SWINE, (2012), pages 841 - 55
		- LAPOINTE ET AL., CAN J VET RES., (2002), vol. 66, pages 8 - 14
		- BAUMS ET AL., CLIN VACCINE IMMUNOL., (2010), vol. 17, pages 1589 - 97
		- WISSELINK HJ ET AL., VET MICROBIOL., (2002), vol. 84, pages 155 - 68
		- BUSQUE ET AL., CAN J VET RES., (1997), pages 275 - 9
		- FITTIPALDI ET AL., VACCINE, (2007), vol. 25, pages 3524 - 35
		- FITTIPALDI ET AL., FUTURE MICROBIOL., (2012), vol. 7, pages 259 - 79
		- CALZAS ET AL., INFECT IMMUN., (2015), vol. 83, pages 441 - 53
		- CHARLAND ET AL., MICROBIOLOGY, (1997), vol. 143, pages 3607 - 14
		- ROY; SHIAO, CHIMIA, (2011), vol. 65, pages 24 - 9
		- HEATH PT, EXPERT REV VACCINES, (2011), vol. 10, pages 685 - 94
		- BAKER ET AL., N ENGL J MED., (1988), vol. 319, pages 1180 - 5
		- KASPER ET AL., J CLIN INVEST., (1996), vol. 98, pages 2308 - 14
		- MOENS ET AL., INFECT IMMUN., (2009), vol. 77, pages 1976 - 80
		- SCHIITZ ET AL., J CLIN IMMUNOL., (2013), vol. 33, pages 288 - 96
		- BAUMS ET AL., CLIN VACCINE IMMUNOL, (2009), vol. 16, pages 200 - 8
		- SAMBROOK; FRITSCH; MANIATIS, Molecular Cloning: A Laboratory Manual, (1989), vol. I, II, I
		- DNA Cloning, (1985), vol. I, II
		- Methods In Enzymology, ACADEMIC PRESS, INC.
		- Protein purification methods - a practical approach, IRL PRESS AT OXFORD UNIVERSITY PRESS
		- Handbook of Experimental Immunology, SCIENTIFIC PUBLICATIONS, (1986), vol. I-IV
		- "Carbohydrate-based vaccines", R. ROY, ACS Symposium Series, (2008), page 989
		- "Carbohydrate-based vaccines", R. ROY, ACS Symp. Ser, (2008), vol. 989
		- HUNTER ET AL., The Theory and Practical Application of Adjuvants, JOHNWILEY AND SONS, (1995), pages 51 - 94
		- TODD ET AL., VACCINE, (1997), vol. 15, pages 564 - 570
		- Vaccine Design, The Subunit and Adjuvant Approach, PLENUM PRESS, (1995), page 147
		- PHAMEUROPA, (199606), vol. 8, no. 2
		- VAN CALSTEREN ET AL., BIOCHEM CELL BIOL., (2010), vol. 88, pages 513 - 25
		- SEGURA ET AL., INFECT IMMUN., (1999), vol. 67, pages 4646 - 54
		- CALZAS ET AL., INFECT IMMUN., (2013), vol. 81, pages 3106 - 18
		- HIGGINS; GOTTSCHALK, J VET DIAGN INVEST., (1990), vol. 2, pages 249 - 52
		- GOYETTE-DESJARDINS ET AL., METHODS MOL BIOL., (2015), vol. 1331, pages 81 - 92
		- BYRD; KADIS, INFECT IMMUN., (1992), vol. 60, pages 3042 - 51
		- CALZAS ET AL., INFECT IMMUN, (2013), vol. 81, pages 3106 - 18
		- SZU ET AL., CARBOHYDR RES., (1986), vol. 152, pages 7 - 20
		- DUAN; KASPER, GLYCOBIOLOGY, (2011), vol. 21, pages 401 - 9
		- HIGASHI ET AL., CARBOHYDR POLYM, (2011), vol. 86, pages 1365 - 70
		- ANDERSON P., INFECT IMMUN, (1983), vol. 39, pages 233 - 8
		- SVENSON ET AL., FEMS MICROBIOL LETT, (1977), vol. 1, pages 145 - 7
		- SVENSON ET AL., J IMMUNOL METHODS, (1979), vol. 25, pages 323 - 35
		- WESSELS ET AL., PROC NATL ACAD SCI, (1987), vol. 84, pages 9170 - 4
		- PAOLETTI ET AL., J BIOL CHEM, (1990), vol. 265, pages 18278 - 83
		- PAWLOWSKI; SVENSON, FEMS MICROBIOL LETT, (1999), vol. 174, pages 255 - 63
		- VAN CALSTEREN ET AL., BIOCHEM CELL BIOL, (2013), vol. 91, pages 49 - 58
		- REUTER ET AL., GLYCOCONJ J, (1989), vol. 6, pages 35 - 44
		- HOUDE ET AL., INFECT IMMUN., (2012), vol. 80, pages 506 - 17
		- WESSELS ET AL., J CLIN INVEST, (1990), vol. 86, pages 1428 - 33
		- O'HAGAN; VALIANTE, NAT REV DRUG DISCOV., (2003), vol. 2, pages 727 - 35
		- CHU ET AL., INFECT IMMUN., (2000), vol. 68, pages 1450 - 6
		- FATTOM ET AL., VACCINE, (1995), vol. 13, pages 1288 - 93
		- BODE ET AL., EXPERT REV VACCINES, (2011), vol. 10, pages 499 - 511
	- CHU ET AL., J EXP MED., (1997), vol. 186, pages 1623 - 31
	- KOVARIK ET AL., IMMUNOLOGY, (2001), vol. 102, pages 67 - 76
	- STILLS HF., ILAR JOURNAL, (2005), vol. 46, pages 280 - 93
	- LEENAARS ET AL., VET IMMUNOL IMMUNOPATHOL., (1994), vol. 40, pages 225 - 41
	- BENNETT ET AL., J IMMUNOL METHODS, (1992), vol. 153, pages 31 - 40
	- SOMMARIVA ET AL., J TRANSL MED., (2013), vol. 11, page 25
	- JENNINGS, ILAR JOURNAL, (1995), vol. 37, pages 119 - 25
	- KATEREGGA ET AL., BMC VET RES., (2012), vol. 8, page 63
	- PLOTKIN SA., CLIN VACCINE IMMUNOL., (2010), vol. 17, pages 1055 - 65
	- SONG JY ET AL., J INFECT CHEMOTHER., (2013), vol. 19, pages 412 - 25
	- ROMERO-STEINER ET AL., CLIN VACCINE IMMUNOL., (2006), vol. 13, pages 165 - 9
	- GUILLIAMS ET AL., NAT REV IMMUNOL., (2014), vol. 14, pages 94 - 108
	- UNDERHILL; OZINSKY, ANNU REV IMMUNOL., (2002), vol. 20, pages 825 - 52
	- RICKLIN ET AL., NAT IMMUNOL., (2010), vol. 11, pages 785 - 97
	- LEE ET AL., CRIT REV MICROBIOL., (2003), vol. 29, pages 333 - 49
	- PERLMUTTER ET AL., J IMMUNOL., (1978), vol. 121, pages 566 - 72
	- RUBINSTEIN; STEIN, J IMMUNOL., (1988), vol. 141, pages 4352 - 6
	- SCHREIBER ET AL., J INFECT DIS., (1993), vol. 167, pages 221 - 6
	- MICHAELSEN ET AL., SCAND J IMMUNOL., (2004), vol. 59, pages 34 - 9
	- MCLAY ET AL., J IMMUNOL., (2002), vol. 168, pages 3437 - 43
	- WISSELINK ET AL., VET MICROBIOL., (2002), vol. 84, pages 155 - 68
	- SWILDENS ET AL., VET REC., (2007), vol. 160, pages 619 - 21
	- GALINA ET AL., CAN J VET RES., (1996), vol. 60, pages 72 - 4
	- GOTTSCHALK ET AL., CAN J VET RES., (1998), vol. 62, pages 75 - 9
	- OKWUMABUA ET AL., FEMS MICROBIOL LETT., (1999), vol. 181, pages 113 - 21
	- FITTIPALDI ET AL., EMERG INFECT DIS., (2011), vol. 17, pages 2239 - 44
	- LI Y ET AL., INFECT IMMUN., (2006), vol. 74, pages 305 - 12
	- "Streptococcosis", GOTTSCHALK M., Diseases of swine, WILEY-BLACKWELL PUBLISHING, (2012), pages 841 - 55
	- FIELD HI; BUNTAIN D; DONE JT., "Studies on piglet mortality. I. Streptococcal meningitis and arthritis", VET REC, (1954), vol. 66, pages 453 - 5
	- JANSEN EJ; DORSSEN CA., "Meningo-encephalitis in pigs caused by Streptococci", TIJDSCHR DIERGENEESKD, (1951), vol. 76, pages 815 - 32
	- DE MOOR CE., "Septicaemic infections in pigs, caused by haemolytic Streptococci of new Lancefield groups designated R, S and T.", ANTONIE VAN LEEUWENHOEK, (1963), vol. 29, pages 272 - 80
	- ELLIOTT SD., "Streptococcal infection in young pigs. I. An immunochemical study of the causative agent (PM Streptococcus", J HYG (LOND, (1966), vol. 64, pages 205 - 12
	- WINDSOR RS; ELLIOTT SD., "Streptococcal infection in young pigs. IV. An outbreak of streptococcal meningitis in weaned pigs", J HYG (LOND, (1975), vol. 75, pages 69 - 78
	- GOYETTE-DESJARDINS G; AUGER JP; XU J; SEGURA M; GOTTSCHALK M., "Streptococcus suis, an important pig pathogen and emerging zoonotic agent-an update on the worldwide distribution based on serotyping and sequence typing", EMERG MICROBES INFECT, (2014), vol. 3, page E45
	- "Streptococcal diseases", HIGGINS R; GOTTSCHALK M., Diseases of swine, BLACKWELL PUBLISHING, (2006), pages 769 - 83
	- SANFORD SE; TILKER ME., "Streptococcus suis type II-associated diseases in swine: observations of a one-year study", J AM VET MED ASSOC, (1982), vol. 181, pages 673 - 6
	- CLOUTIER G; D'ALLAIRE S; MARTINEZ G; SURPRENANT C; LACOUTURE S; GOTTSCHALK M., "Epidemiology of Streptococcus suis serotype 5 infection in a pig herd with and without clinical disease", VET MICROBIOL, (2003), vol. 97, pages 135 - 51
	- SEGURA M., "Fisher scientific award lecture - The capsular polysaccharides of Group B Streptococcus and Streptococcus suis differently modulate bacterial interactions with dendritic cells", CAN J MICROBIOL, (2012), vol. 58, pages 249 - 60
	- LAPOINTE L; D'ALLAIRE S; LEBRUN A; LACOUTURE S; GOTTSCHALK M., "Antibody response to an autogenous vaccine and serologic profile for Streptococcus suis capsular type 1/2", CAN J VET RES, (2002), vol. 66, pages 8 - 14
	- BAUMS CG; BRIIGGEMANN C; KOCK C; BEINEKE A; WALDMANN K-H; VALENTIN-WEIGAND P., "Immunogenicity of an autogenous Streptococcus suis bacterin in preparturient sows and their piglets in relation to protection after weaning", CLIN VACCINE IMMUNOL, (2010), vol. 17, pages 1589 - 97
	- WISSELINK HJ; STOCKHOFE-ZURWIEDEN N; HILGERS LAT; SMITH HE., "Assessment of protective efficacy of live and killed vaccines based on a non-encapsulated mutant of Streptococcus suis serotype 2", VET MICROBIOL, (2002), vol. 84, pages 155 - 68
	- BUSQUE P; HIGGINS R; CAYA F; QUESSY S., "Immunization of pigs against Streptococcus suis serotype 2 infection using a live avirulent strain", CAN J VET RES, (1997), vol. 61, pages 275 - 9
	- FITTIPALDI N; HAREL J; D'AMOURS B; LACOUTURE S; KOBISCH M; GOTTSCHALK M., "Potential use of an unencapsulated and aromatic amino acid-auxotrophic Streptococcus suis mutant as a live attenuated vaccine in swine", VACCINE, (2007), vol. 25, doi:doi:10.1016/j.vaccine.2007.01.084, pages 3524 - 35, XP022032559 DOI: http://dx.doi.org/10.1016/j.vaccine.2007.01.084
	- FITTIPALDI N; SEGURA M; GRENIER D; GOTTSCHALK M., "Virulence factors involved in the pathogenesis of the infection caused by the swine pathogen and zoonotic agent Streptococcus suis", FUTURE MICROBIOL, (2012), vol. 7, pages 259 - 79
	- CALZAS C; LEMIRE P; AURAY G; GERDTS V; GOTTSCHALK M; SEGURA M, "Antibody response specific to the capsular polysaccharide is impaired in Streptococcus suis serotype 2-infected animals", INFECT IMMUN, (2015), vol. 83, pages 441 - 53
	- SONG JY; MOSELEY MA; BURTON RL; NAHM MH., "Pneumococcal vaccine and opsonic pneumococcal antibody", J INFECT CHEMOTHER, (2013), vol. 19, pages 412 - 25
	- HEATH PT., "An update on vaccination against Group B Streptococcus", EXPERT REV VACCINES, (2011), vol. 10, doi:doi:10.1586/erv.11.61, pages 685 - 94, XP009192824 DOI: http://dx.doi.org/10.1586/erv.11.61
	- BOTTOMLEY MJ; SERRUTO D; SAFADI MAP; KLUGMAN KP, "Future challenges in the elimination of bacterial meningitis", VACCINE, (2012), vol. 30, pages B78 - B86
	- ROY R; SHIAO TC., "Organic chemistry and immunochemical strategies in the design of potent carbohydrate-based vaccines", CHIMIA, (2011), vol. 65, pages 24 - 9
	- ELLIOTT SD; CLIFTON-HADLEY F; TAI J., "Streptococcal infection in young pigs. V. An immunogenic polysaccharide from Streptococcus suis type 2 with particular reference to vaccination against streptococcal meningitis in pigs", J HYG (LOND, (1980), vol. 85, pages 275 - 85, XP000857913
	- CHARLAND N; JACQUES M; LACOUTURE S; GOTTSCHALK M., "Characterization and protective activity of a monoclonal antibody against a capsular epitope shared by Streptococcus suis serotypes 1, 2 and 1/2", MICROBIOLOGY, (1997), vol. 143, pages 3607 - 14
	- KNUF M; KOWALZIK F; KIENINGER D., "Comparative effects of carrier proteins on vaccine-induced immune response", VACCINE, (2011), vol. 29, doi:doi:10.1016/j.vaccine.2011.04.053, pages 4881 - 90, XP028379356 DOI: http://dx.doi.org/10.1016/j.vaccine.2011.04.053
	- BYRD W; KADIS S., "Preparation, characterization, and immunogenicity of conjugate vaccines directed against Actinobacillus pleuropneumoniae virulence determinants", INFECT IMMUN, (1992), vol. 60, pages 3042 - 51
	- BYRD W; HARMON BG; KADIS S., "Protective efficacy of conjugate vaccines against experimental challenge with porcine Actinobacillus pleuropneumoniae", VET IMMUNOL IMMUNOPATHOL, (1992), vol. 34, doi:doi:10.1016/0165-2427(92)90172-M, pages 307 - 24, XP023795768 DOI: http://dx.doi.org/10.1016/0165-2427(92)90172-M
	- ANDRESEN LO; JACOBSEN MJ; NIELSEN JP., "Experimental vaccination of pigs with an Actinobacillus pleuropneumoniae serotype 5b capsular polysaccharide-tetanus toxoid conjugate", ACTA VET SCAND, (1997), vol. 38, pages 283 - 93
	- VAN CALSTEREN MR; GAGNON F; LACOUTURE S; FITTIPALDI N; GOTTSCHALK M., "Structure determination of Streptococcus suis serotype 2 capsular polysaccharide", BIOCHEM CELL BIOL, (2010), vol. 88, pages 513 - 25
	- SEGURA M; STANKOVA J; GOTTSCHALK M., "Heat-killed Streptococcus suis capsular type 2 strains stimulate tumor necrosis factor alpha and interleukin-6 production by murine macrophages", INFECT IMMUN, (1999), vol. 67, pages 4646 - 54
	- CALZAS C; GOYETTE-DESJARDINS G; LEMIRE P; GAGNON F; LACHANCE C; VAN CALSTEREN MR ET AL., "Group B Streptococcus and Streptococcus suis capsular polysaccharides induce chemokine production by dendritic cells via Toll-like receptor 2- and MyD88-dependent and -independent pathways", INFECT IMMUN, (2013), vol. 81, pages 3106 - 18, XP002765279
	- VAN CALSTEREN MR; GAGNON F; CALZAS C; GOYETTE-DESJARDINS G; OKURA M; TAKAMATSU D ET AL., "Structure determination of Streptococcus suis serotype 14 capsular polysaccharide", BIOCHEM CELL BIOL, (2013), vol. 91, pages 49 - 58
	- HOUDE M; GOTTSCHALK M; GAGNON F; VAN CALSTEREN M-R; SEGURA M., "Streptococcus suis Capsular Polysaccharide Inhibits Phagocytosis through Destabilization of Lipid Microdomains and Prevents Lactosylceramide-Dependent Recognition", INFECT IMMUN, (2012), vol. 80, pages 506 - 17
	- HIGGINS R; GOTTSCHALK M., "An update on Streptococcus suis identification", J VET DIAGN INVEST, (1990), vol. 2, pages 249 - 52
	- "Murine whole-blood opsonophagocytosis assay to evaluate protection by antibodies raised against encapsulated extracellular bacteria", GOYETTE-DESJARDINS G; ROY R; SEGURA M., Methods in Molecular Biology - Carbohydrate-based vaccines, SPRINGER
	- SZU SC; ZON G; SCHNEERSON R; ROBBINS JB, "Ultrasonic irradiation of bacterial polysaccharides. Characterization of the depolymerized products and some applications of the process", CARBOHYDR RES, (1986), vol. 152, pages 7 - 20
	- REUTER G; SCHAUER R; SZEIKI C; KAMERLING JP; VLIEGENTHART JF., "A detailed study of the periodate oxidation of sialic acids in glycoproteins", GLYCOCONJ J, (1989), vol. 6, pages 35 - 44
	- WESSELS MR; PAOLETTI LC; KASPER DL; DIFABIO JL; MICHON F; HOLME K ET AL., "Immunogenicity in animals of a polysaccharide-protein conjugate vaccine against type III Group B Streptococcus", J CLIN INVEST, (1990), vol. 86, pages 1428 - 33, XP002546281
	- MERRIL C; GOLDMAN D; SEDMAN S; EBERT M, "Ultrasensitive stain for proteins in polyacrylamide gels shows regional variation in cerebrospinal fluid proteins", SCIENCE, (1981), vol. 211, pages 1437 - 8
	- CHU RS; TARGONI OS; KRIEG AM; LEHMANN PV; HARDING CV, "CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Thl) immunity", J EXP MED, (1997), vol. 186, doi:doi:10.1084/jem.186.10.1623, pages 1623 - 31, XP002910130 DOI: http://dx.doi.org/10.1084/jem.186.10.1623
	- STILLS HF., "Adjuvants and antibody production: dispelling the myths associated with Freund's complete and other adjuvants", ILAR JOURNAL, (2005), vol. 46, pages 280 - 93
	- LEENAARS PPAM; HENDRIKSEN CFM; ANGULO AF; KOEDAM MA; CLAASSEN E., "Evaluation of several adjuvants as alternatives to the use of Freund's adjuvant in rabbits", VET IMMUNOL IMMUNOPATHOL, (1994), vol. 40, doi:doi:10.1016/0165-2427(94)90022-1, pages 225 - 41, XP023690027 DOI: http://dx.doi.org/10.1016/0165-2427(94)90022-1
	- BENNETT B; CHECK IJ; OLSEN MR; HUNTER RL., "A comparison of commercially available adjuvants for use in research", J IMMUNOL METHODS, (1992), vol. 153, doi:doi:10.1016/0022-1759(92)90302-A, pages 31 - 40, XP023657883 DOI: http://dx.doi.org/10.1016/0022-1759(92)90302-A
	- SOMMARIVA M; DE CESARE M; MEINI A; CATALDO A; ZAFFARONI N; TAGLIABUE E ET AL., "efficacy of CpG-ODN, cetuximab and cisplatin combination for very advanced ovarian xenograft tumors", J TRANSL MED, (2013), vol. 11, doi:doi:10.1186/1479-5876-11-25, page 25, XP021139685 DOI: http://dx.doi.org/10.1186/1479-5876-11-25
	- JENNINGS VM., "Review of selected adjuvants used in antibody production", ILAR JOURNAL, (1995), vol. 37, pages 119 - 25
	- KATEREGGA J; LUBEGA GW; LINDBLAD EB; AUTHIE E; COETZER TH; BOULANGE AF., "Effect of adjuvants on the humoral immune response to congopain in mice and cattle", BMC VET RES, (2012), vol. 8, doi:doi:10.1186/1746-6148-8-63, page 63, XP021129622 DOI: http://dx.doi.org/10.1186/1746-6148-8-63
	- DALSGAARD K; HILGERS L; TROUVE G., "Classical and new approaches to adjuvant use in domestic food animals", ADV VET SCI COMP MED, (1990), vol. 35, pages 121 - 60
	- PLOTKIN SA., "Correlates of protection induced by vaccination", CLIN VACCINE IMMUNOL, (2010), vol. 17, pages 1055 - 65
	- SWILDENS B; NIELEN M; WISSELINK HJ; VERHEIJDEN JHM; STEGEMAN JA, "Elimination of strains of Streptococcus suis serotype 2 from the tonsils of carrier sows by combined medication and vaccination", VET REC, (2007), vol. 160, pages 619 - 21
	- GILBERT FB; POUTREL B; SUTRA L., "Immunogenicity in cows of Staphylococcus aureus type 5 capsular polysaccharide-ovalbumin conjugate", VACCINE, (1994), vol. 12, doi:doi:10.1016/0264-410X(94)90103-1, pages 369 - 74, XP023711582 DOI: http://dx.doi.org/10.1016/0264-410X(94)90103-1
	- LEE C-J; LEE LH; FRASCH CE., "Protective immunity of pneumococcal glycoconjugates", CRIT REV MICROBIOL, (2003), vol. 29, pages 333 - 49
	- BAKER CJ; RENCH MA; EDWARDS MS; CARPENTER RJ; HAYS BM; KASPER DL., "Immunization of pregnant women with a polysaccharide vaccine of Group B Streptococcus", N ENGL J MED, (1988), vol. 319, pages 1180 - 5
	- KASPER DL; PAOLETTI LC; WESSELS MR; GUTTORMSEN HK; CAREY VJ; JENNINGS HJ ET AL., "Immune response to type III Group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine", J CLIN INVEST, (1996), vol. 98, pages 2308 - 14
	- MOENS L; JEURISSEN A; NIERKENS S; BOON L; VAN KAER L; KASRAN A ET AL., "Generation of antibody responses to pneumococcal capsular polysaccharides is independent of CD1 expression in mice", INFECT IMMUN, (2009), vol. 77, pages 1976 - 80
	- SCHIITZ K; HUGHES R; PARKER A; QUINTI I; THON V; CAVALIERE M ET AL., "Kinetics of IgM and IgA antibody response to 23-valent pneumococcal polysaccharide vaccination in healthy subjects", J CLIN IMMUNOL, (2013), vol. 33, pages 288 - 96
	- BAUMS CG; KOCK C; BEINEKE A; BENNECKE K; GOETHE R; SCHRODER C ET AL., "Streptococcus suis bacterin and subunit vaccine immunogenicities and protective efficacies against serotypes 2 and 9", CLIN VACCINE IMMUNOL, (2009), vol. 16, pages 200 - 8
	- DUAN J; KASPER DL., "Oxidative depolymerization of polysaccharides by reactive oxygen/nitrogen species", GLYCOBIOLOGY, (2011), vol. 21, pages 401 - 9
	- HIGASHI K; LY M; WANG Z; MASUKO S; BHASKAR U; STERNER E ET AL., "Controlled photochemical depolymerization of K5 heparosan, a bioengineered heparin precursor", CARBOHYDR POLYM, (2011), vol. 86, pages 1365 - 70
	- ANDERSON P., "Antibody responses to Haemophilus influenzae type b and diphtheria toxin induced by conjugates of oligosaccharides of the type b capsule with the nontoxic protein CRM197", INFECT IMMUN, (1983), vol. 39, pages 233 - 8
	- SVENSON SB; LINDBERG AA., "Oligosaccharide-protein conjugate: A novel approach for making Salmonella O-antigen immunogens", FEMS MICROBIOL LETT, (1977), vol. 1, doi:doi:10.1111/j.1574-6968.1977.tb00601.x, pages 145 - 7, XP023717080 DOI: http://dx.doi.org/10.1111/j.1574-6968.1977.tb00601.x
	- SVENSON SB; LINDBERG AA., "Coupling of acid labile Salmonella specific oligosaccharides to macromolecular carriers", J IMMUNOL METHODS, (1979), vol. 25, doi:doi:10.1016/0022-1759(79)90025-5, pages 323 - 35, XP024017647 DOI: http://dx.doi.org/10.1016/0022-1759(79)90025-5
	- WESSELS MR; MUNOZ A; KASPER DL., "A model of high-affinity antibody binding to type III Group B Streptococcus capsular polysaccharide", PROC NATL ACAD SCI, (1987), vol. 84, pages 9170 - 4
	- PAOLETTI LC; KASPER DL; MICHON F; DIFABIO J; HOLME K; JENNINGS HJ ET AL., "An oligosaccharide-tetanus toxoid conjugate vaccine against type III Group B Streptococcus", J BIOL CHEM, (1990), vol. 265, pages 18278 - 83, XP002301343
	- PAWLOWSKI A; SVENSON SB, "Electron beam fragmentation of bacterial polysaccharides as a method of producing oligosaccharides for the preparation of conjugate vaccines", FEMS MICROBIOL LETT, (1999), vol. 174, doi:doi:10.1111/j.1574-6968.1999.tb13577.x, pages 255 - 63, XP055262001 DOI: http://dx.doi.org/10.1111/j.1574-6968.1999.tb13577.x
	- PAOLETTI LC; WESSELS MR; MICHON F; DIFABIO J; JENNINGS HJ; KASPER DL, "Group B Streptococcus type II polysaccharide-tetanus toxoid conjugate vaccine", INFECT IMMUN, (1992), vol. 60, pages 4009 - 14, XP000601510
	- WESSELS MR; PAOLETTI LC; RODEWALD AK; MICHON F; DIFABIO J; JENNINGS HJ ET AL., "Stimulation of protective antibodies against type la and Ib Group B Streptococci by a type la polysaccharide-tetanus toxoid conjugate vaccine", INFECT IMMUN, (1993), vol. 61, pages 4760 - 6
	- PAOLETTI LC; WESSELS MR; RODEWALD AK; SHROFF AA; JENNINGS HJ; KASPER DL., "Neonatal mouse protection against infection with multiple Group B streptococcal (GBS) serotypes by maternal immunization with a tetravalent GBS polysaccharide-tetanus toxoid conjugate vaccine", INFECT IMMUN, (1994), vol. 62, pages 3236 - 43, XP001148813
	- WESSELS MR; PAOLETTI LC; PINEL J; KASPER DL., "Immunogenicity and protective activity in animals of a type V Group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine", J INFECT DIS, (1995), vol. 171, pages 879 - 84, XP000674380
	- PAOLETTI LC; PINEL J; JOHNSON KD; REINAP B; ROSS RA; KASPER DL., "Synthesis and preclinical evaluation of glycoconjugate vaccines against Group B Streptococcus types VI and VIII", J INFECT DIS, (1999), vol. 180, pages 892 - 5
	- PAOLETTI LC; KASPER DL., "Conjugate vaccines against Group B Streptococcus types IV and VII", J INFECT DIS, (2002), vol. 186, pages 123 - 6
	- WESSELS MR; PAOLETTI LC; GUTTORMSEN HK; MICHON F; D'AMBRA AJ; KASPER DL., "Structural properties of Group B streptococcal type III polysaccharide conjugate vaccines that influence immunogenicity and efficacy", INFECT IMMUN, (1998), vol. 66, pages 2186 - 92, XP009113849
	- JENNINGS HJ; LUGOWSKI C; KASPER DL., "Conformational aspects critical to the immunospecificity of the type III Group B streptococcal polysaccharide", BIOCHEMISTRY, (1981), vol. 20, pages 4511 - 8
	- ZOU W; MACKENZIE R; THERIEN L; HIRAMA T; YANG Q; GIDNEY MA ET AL., "Conformational epitope of the type III Group B Streptococcus capsular polysaccharide", J IMMUNOL, (1999), vol. 163, pages 820 - 5
	- AVCI FY; LI X; TSUJI M; KASPER DL., "A mechanism for glycoconjugate vaccine activation of the adaptive immune system and its implications for vaccine design", NAT MED, (2011), vol. 17, doi:doi:10.1038/nm.2535, pages 1602 - 9, XP055179286 DOI: http://dx.doi.org/10.1038/nm.2535
	- MICHON F; UITZ C; SARKAR A; D'AMBRA AJ; LAUDE-SHARP M; MOORE S ET AL., "Group B streptococcal type II and III conjugate vaccines: physicochemical properties that influence immunogenicity", CLIN VACCINE IMMUNOL, (2006), vol. 13, doi:doi:10.1128/CVI.00122-06, pages 936 - 43, XP055211257 DOI: http://dx.doi.org/10.1128/CVI.00122-06
	- O'HAGAN DT; VALIANTE NM., "Recent advances in the discovery and delivery of vaccine adjuvants", NAT REV DRUG DISCOV, (2003), vol. 2, pages 727 - 35
	- CHU RS; MCCOOL T; GREENSPAN NS; SCHREIBER JR; HARDING CV., "CpG oligodeoxynucleotides act as adjuvants for pneumococcal polysaccharide-protein conjugate vaccines and enhance antipolysaccharide immunoglobulin G2a (IgG2a) and IgG3 antibodies", INFECT IMMUN, (2000), vol. 68, pages 1450 - 6
	- FATTOM A; LI X; CHO YH; BURNS A; HAWWARI A; SHEPHERD SE ET AL., "Effect of conjugation methodology, carrier protein, and adjuvants on the immune response to Staphylococcus aureus capsular polysaccharides", VACCINE, (1995), vol. 13, doi:doi:10.1016/0264-410X(95)00052-3, pages 1288 - 93, XP004057429 DOI: http://dx.doi.org/10.1016/0264-410X(95)00052-3
	- BODE C; ZHAO G; STEINHAGEN F; KINJO T; KLINMAN DM., "CpG DNA as a vaccine adjuvant", EXPERT REV VACCINES, (2011), vol. 10, doi:doi:10.1586/erv.10.174, pages 499 - 511, XP055138146 DOI: http://dx.doi.org/10.1586/erv.10.174
	- KOVARIK J; BOZZOTTI P; TOUGNE C; DAVIS HL; LAMBERT PH; KRIEG AM ET AL., "Adjuvant effects of CpG oligodeoxynucleotides on responses against T-independent type 2 antigens", IMMUNOLOGY, (2001), vol. 102, pages 67 - 76
	- COX JC; COULTER AR., "Adjuvants-A classification and review of their modes of action", VACCINE, (1997), vol. 15, doi:doi:10.1016/S0264-410X(96)00183-1, pages 248 - 56, XP004094403 DOI: http://dx.doi.org/10.1016/S0264-410X(96)00183-1
	- LEENAARS PP; SAVELKOUL HF; HENDRIKSEN CF; VAN ROOIJEN N; CLAASSEN E., "Increased adjuvant efficacy in stimulation of antibody responses after macrophage elimination in vivo", IMMUNOLOGY, (1997), vol. 90, pages 337 - 43
	- HEEGAARD P; DEDIEU L; JOHNSON N; LE POTIER M-F; MOCKEY M; MUTINELLI F ET AL., "Adjuvants and delivery systems in veterinary vaccinology: current state and future developments", ARCH VIROL, (2011), vol. 156, doi:doi:10.1007/s00705-010-0863-1, pages 183 - 202, XP019878345 DOI: http://dx.doi.org/10.1007/s00705-010-0863-1
	- HUNTER RL., "Overview of vaccine adjuvants: present and future", VACCINE, (2002), vol. 20, no. 3, pages 7 - 12
	- "Preparation of polysaccharide-conjugate vaccines", PEETERS CC; LAGERMAN PR; WEERS O; OOMEN LA; HOOGERHOUT P; BEURRET M ET AL., Methods in Molecular Medecine - Vaccine Protocols, HUMANA PRESS INC, (2003), pages 153 - 73
	- WILSON D; BRALEY-MULLEN H., "Antigen requirements for priming of type III pneumococcal polysaccharide-specific IgG memory responses: suppression of memory with the T-independent form of antigen", CELL IMMUNOL, (1981), vol. 64, doi:doi:10.1016/0008-8749(81)90468-8, pages 177 - 86, XP024007446 DOI: http://dx.doi.org/10.1016/0008-8749(81)90468-8
	- PEETERS CCAM; TENBERGEN-MEEKES A-MJ; POOLMAN JT; ZEGERS BJM; RIJKERS GT., "Immunogenicity of a Streptococcus pneumoniae type 4 polysaccharide-protein conjugate vaccine is decreased by admixture of high doses of free saccharide", VACCINE, (1992), vol. 10, doi:doi:10.1016/0264-410X(92)90046-M, pages 833 - 40, XP023710393 DOI: http://dx.doi.org/10.1016/0264-410X(92)90046-M
	- RODRIGUEZ ME; VAN DEN DOBBELSTEEN GP; OOMEN LA; DE WEERS O; VAN BUREN L; BEURRET M ET AL., "Immunogenicity of Streptococcus pneumoniae type 6B and 14 polysaccharide-tetanus toxoid conjugates and the effect of uncoupled polysaccharide on the antigen-specific immune response", VACCINE, (1998), vol. 16, doi:doi:10.1016/S0264-410X(98)00129-7, pages 1941 - 9, XP004138440 DOI: http://dx.doi.org/10.1016/S0264-410X(98)00129-7
	- ROMERO-STEINER S; FRASCH CE; CARLONE G; FLECK RA; GOLDBLATT D; NAHM MH, "Use of opsonophagocytosis for serological evaluation of pneumococcal vaccines", CLIN VACCINE IMMUNOL, (2006), vol. 13, doi:doi:10.1128/CVI.13.2.165-169.2006, pages 165 - 9, XP002622149 DOI: http://dx.doi.org/10.1128/CVI.13.2.165-169.2006
	- GUILLIAMS M; BRUHNS P; SAEYS Y; HAMMAD H; LAMBRECHT BN., "The function of Fcg receptors in dendritic cells and macrophages", NAT REV IMMUNOL, (2014), vol. 14, pages 94 - 108
	- UNDERHILL DM; OZINSKY A., "Phagocytosis of microbes: complexity in action", ANNU REV IMMUNOL, (2002), vol. 20, pages 825 - 52
	- RICKLIN D; HAJISHENGALLIS G; YANG K; LAMBRIS JD, "Complement: a key system for immune surveillance and homeostasis", NAT IMMUNOL, (2010), vol. 11, doi:doi:10.1038/ni.1923, pages 785 - 97, XP055306904 DOI: http://dx.doi.org/10.1038/ni.1923
	- PERLMUTTER RM; HANSBURG D; BRILES DE; NICOLOTTI RA; DAVID JM, "Subclass Restriction of Murine Anti-Carbohydrate Antibodies", J IMMUNOL, (1978), vol. 121, pages 566 - 72
	- RUBINSTEIN LJ; STEIN KE, "Murine immune response to the Neisseria meningitidis group C capsular polysaccharide. I. Ontogeny", J IMMUNOL, (1988), vol. 141, pages 4352 - 6
	- SCHREIBER JR; COOPER LJN; DIEHN S; DAHLHAUSER PA; TOSI MF; GLASS DD ET AL., "Variable region-identical monoclonal antibodies of different IgG subclass directed to Pseudomonas aeruginosa lipopolysaccharide O-specific side chain function differently", J INFECT DIS, (1993), vol. 167, pages 221 - 6, XP009027285
	- MICHAELSEN TE; KOLBERG J; AASE A; HERSTAD TK; H IBY EA, "The four mouse IgG isotypes differ extensively in bactericidal and opsonophagocytic activity when reacting with the P1.16 epitope on the outer membrane PorA protein of Neisseria meningitidis", SCAND J IMMUNOL, (2004), vol. 59, pages 34 - 9
	- MCLAY J; LEONARD E; PETERSEN S; SHAPIRO D; GREENSPAN NS; SCHREIBER JR, "y3 gene-disrupted mice selectively deficient in the dominant IgG subclass made to bacterial polysaccharides. II. Increased susceptibility to fatal pneumococcal sepsis due to absence of anti-polysaccharide IgG3 is corrected by induction of anti-polysaccharide IgGl", J IMMUNOL, (2002), vol. 168, pages 3437 - 43
	- GALINA L; VECHT U; WISSELINK HJ; PIJOAN C, "Prevalence of various phenotypes of Streptococcus suis isolated from swine in the U.S.A. based on the presence of muraminidase-released protein and extracellular factor", CAN J VET RES, (1996), vol. 60, pages 72 - 4
	- GOTTSCHALK M; LEBRUN A; WISSELINK H; DUBREUIL JD; SMITH H; VECHT U., "Production of virulence-related proteins by Canadian strains of Streptococcus suis capsular type 2", CAN J VET RES, (1998), vol. 62, pages 75 - 9
	- OKWUMABUA O; ABDELMAGID O; CHENGAPPA MM., "Hybridization analysis of the gene encoding a hemolysin (suilysin) of Streptococcus suis type 2: evidence for the absence of the gene in some isolates", FEMS MICROBIOL LETT, (1999), vol. 181, pages 113 - 21
	- FITTIPALDI N; XU J; LACOUTURE S; THARAVICHITKUL P; OSAKI M; SEKIZAKI T ET AL., "Lineage and virulence of Streptococcus suis serotype 2 isolates from North America", EMERG INFECT DIS, (2011), vol. 17, pages 2239 - 44
	- LI Y; MARTINEZ G; GOTTSCHALK M; LACOUTURE S; WILLSON P; DUBREUIL JD ET AL., "Identification of a surface protein of Streptococcus suis and evaluation of its immunogenic and protective capacity in pigs", INFECT IMMUN, (2006), vol. 74, doi:doi:10.1128/IAI.74.1.305-312.2006, pages 305 - 12, XP008078285 DOI: http://dx.doi.org/10.1128/IAI.74.1.305-312.2006

The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.

Legal notice
Terms of use
24.2.25; 34p